Big pharma dominates ranking of stocks with best five-year returns
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Big pharma dominates ranking of stocks with best five-year returns
May 5, 2016 3:25 PM EDT
Baird maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN), and cut the price target to $505.00 (from $526.00), following the company's 1Q earnings report. EPS of $2.57 was reported in-line with expectations. Baird continues to believe that the copmant can deliver growth over the next few... More
May 4, 2016 8:43 AM EDT
Oppenheimer maintained an Outperform rating on Gilead Sciences (NASDAQ: GILD), and cut the price target to $116.00 (from $120.00), following the company's 1Q earnings report. Gilead reported 1Q16 revenues of $7.79B, below consensus estimates of $8.06B. The top line miss was due to soft sales from... More
May 3, 2016 2:52 PM EDT
Leerink affirms Biogen (Nasdaq: BIIB) with a Market Perform rating and $319 price target following news that the company is going to spin-off its hemophilia unit.
Analyst Geoffrey Porges commented: In a somewhat surprising move, Biogen announced today that it will spin off its hemophilia business into an... More
